Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen receives NICE recommendation for Invokana

Janssen receives NICE recommendation for Invokana

27th June 2014

Janssen has been granted a recommendation for its type 2 diabetes therapy Invokana from the National Institute for Health and Care Excellence (NICE).

The canagliflozin-based therapy has been approved as a means of lowering blood sugar levels in people with type 2 diabetes when used in combination with other antidiabetic drugs, including insulin, within the NHS.

It is the tenth drug to be recommended by NICE for this indication and functions by blocking the reabsorption of glucose in the kidneys, which is instead passed out of the body in the urine.

Since treatment needs can vary from person to person, it is important that clinicians have access to as wide a variety of drugs as possible if they are to successfully control type 2 diabetes in all patients.

Professor Carole Longson, director at the Centre for Health Technology Evaluation at NICE, said: "With this new positive recommendation for canagliflozin, we have added another clinically and cost effective option to the armoury of anti-diabetic drugs."

This comes after Janssen had a related type 2 diabetes product called Vokanamet approved in Europe earlier this year. This fixed-dose therapy combines canagliflozin and immediate-release metformin hydrochloride in a single tablet.ADNFCR-8000103-ID-801731570-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.